Applied DNA Sciences Appoints Bob Miglani as Chief of Business Development

STONY BROOK, NY--(Marketwired - May 05, 2016) - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, has appointed Bob Miglani as Chief of Business Development.

In his new full-time role, Mr. Miglani will be responsible for building the Company's business within the FDA-regulated markets, including pharmaceuticals, foods, personal care and medical devices. He will also lead the team responsible for creating and driving commercial strategies within these large and important sectors.

Mr. Miglani brings 23 years of deep industry experience from Pfizer Inc., where he served in a series of roles of increasing responsibility, most recently as Senior Director, External Medical Affairs. In that role, he led Pfizer's efforts to partner with external medical, scientific and consumer organizations. Over the course of his career, Mr. Miglani has held diverse global positions encompassing sales, marketing research, strategy, pricing & reimbursement, public affairs and policy, market access, patient advocacy, communications and partnership development.

Mr. Miglani has a proven track record of developing innovative partnerships with medical and healthcare organizations in the United States, Europe, India and other parts of the world. In addition to being a Washington Post bestselling author of the book Embrace the Chaos, he is a thought leader on thriving in change and a passionate advocate for embracing disruptive technologies to help society. He earned an MBA from Pace University, a Bachelor of Science degree from Rider University and participated in Executive Leadership Programs at INSEAD and Harvard University.

Mr. Miglani was previously appointed to Applied DNA Sciences' Strategic Advisory Board in March 2016; he will step down from that position to become a full-time member of the Applied DNA Sciences management team.

"Having seen firsthand the capabilities and technology that Applied DNA Sciences offers, I realized that there is a significant opportunity for this solution in the marketplace. We're working in a complex global system where patients are increasingly at greater risk of getting a counterfeit medicine. I believe that Applied DNA Sciences technology offers a unique solution to help track and trace medicines globally, fight counterfeits and provide undisputed proof of origin, helping consumers feel safe and confident and companies feel secure in protecting their brands," Mr. Miglani said. "I look forward to working with my colleagues on the management team to build our business in the pharmaceutical sector and establish meaningful partnerships with partners around the world."

"We are delighted to have Bob join our leadership team as his knowledge, expertise and insight will be an important asset to us as we expand our pharmaceutical solutions," said Dr. James Hayward, President and CEO of Applied DNA Sciences. "One particular area of focus will be to help companies implement new regulations such as the European Union's mandate requiring safety features for medicine packaging to combat counterfeiting of pharmaceuticals. In order to address the increasingly serious issue of counterfeiting that threatens many lives per year worldwide, technologies such as our botanical DNA marking can play a key role, and Bob is well placed to strengthen our sales efforts and strategic relationships in this area."

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Our patented DNA-based solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature^® DNA describes the platform ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW. 

Forward-Looking Statements
The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015,and our subsequent quarterly report on Form 10-Q filed on February 10, 2016 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.